CliffBio
biologic

Epkinly

epcoritamab-bysp

Loss of exclusivityMay 2035projected — 12-year biologic exclusivity estimate
CompanyGenmab →View the full company profile on CliffBio

Drug detail

Brand nameEpkinly
Active ingredientepcoritamab-bysp
Strength4MG/0.8ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalMay 2023
Marketing statusRx

More from Genmab

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Epkinly patent cliff — loss of exclusivity May 2035 | CliffBio